Cutia Therapeutics (HKSE:02487) Other Gross PPE : HK$235.9 Mil (As of Jun. 2024)

View and export this data going back to 2023. Start your Free Trial

What is Cutia Therapeutics Other Gross PPE?

Cutia Therapeutics's Other Gross PPE for the quarter that ended in Jun. 2024 was HK$235.9 Mil.

Cutia Therapeutics's quarterly Other Gross PPE declined from Jun. 2023 (HK$224.2 Mil) to Dec. 2023 (HK$-57.9 Mil) but then increased from Dec. 2023 (HK$-57.9 Mil) to Jun. 2024 (HK$235.9 Mil).

Cutia Therapeutics's annual Other Gross PPE declined from Dec. 2021 (HK$0.0 Mil) to Dec. 2022 (HK$-0.0 Mil) and declined from Dec. 2022 (HK$-0.0 Mil) to Dec. 2023 (HK$-57.9 Mil).

Cutia Therapeutics Other Gross PPE Historical Data

The historical data trend for Cutia Therapeutics's Other Gross PPE can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Cutia Therapeutics Other Gross PPE Chart

Cutia Therapeutics Annual Data

Trend

Dec21

Dec22

Dec23

Other Gross PPE

-57.95

Cutia Therapeutics Semi-Annual Data
	Dec21	Jun22	Dec22	Jun23	Dec23	Jun24
Other Gross PPE	Get a 7-Day Free Trial			-	-	224.24	-57.95	235.86

Cutia Therapeutics Other Gross PPE Calculation

GuruFocus lists Land And Improvements, Buildings And Improvements, Machinery, Furniture, Equipment, Construction In Progress and Other Gross PPE under the "Gross Property, Plant and Equipment" section.

Cutia Therapeutics Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Cutia Therapeutics (HKSE:02487) » Definitions » Other Gross PPE

Comparable Companies

Traded in Other Exchanges

N/A

Address

436 Heng Feng Road, 20th Floor, Huanzhi Building, Jingan District, Shanghai, CHN, 200070

Website

https://www.cutiatx.com

Cutia Therapeutics is a dermatology-focused biopharmaceutical company focused on the broader dermatology treatment and care therapeutic areas, including localized adipose accumulation management medication, scalp diseases and care, skin diseases and care, and topical anesthesia. Its core product is CU-20401, which is a recombinant mutant collagenase that targets obesity, overweight, or other localized adipose accumulation-associated metabolic diseases. Its other products include CU-40102 (topical finasteride spray); CU-10201; CU-40101; and CU-10101 (topical novel small molecule agent) among others. Geographically, the company generates its revenue from the People's Republic of China.

Executives

Zhang Lele	2101 Beneficial owner
Zhang Qiping	2201 Interest of corporation controlled by you
Su Zhou Tong Yu Tou Zi Guan Li He Huo Qi Ye You Xian He Huo	2201 Interest of corporation controlled by you
Su Zhou Tong He Yu Cheng Tou Zi He Huo Qi Ye You Xian He Huo	2101 Beneficial owner
6 Dimensions Capital Gp, Llc	2201 Interest of corporation controlled by you
6 Dimensions Capital, L.p.	2101 Beneficial owner
Su Zhou Yun Zhang Tou Zi Zi Xun You Xian Gong Si	2201 Interest of corporation controlled by you
Yf Dermatology Limited	2101 Beneficial owner
Yunfeng Capital Limited	2102 Investment manager
Yunfeng Fund Iii, L.p.	2201 Interest of corporation controlled by you
Yunfeng Investment Iii, Ltd.	2201 Interest of corporation controlled by you
Pandanus Associates Inc.	2201 Interest of corporation controlled by you
Fil Limited	2201 Interest of corporation controlled by you
Pandanus Partners L.p.	2201 Interest of corporation controlled by you
Hsg Growth V Management, L.p.	2201 Interest of corporation controlled by you

Cutia Therapeutics Headlines

No Headlines